Your session is about to expire
← Back to Search
Kinase Inhibitor
Treatment for Pancreatic Cancer
N/A
Waitlist Available
Research Sponsored by Loxo Oncology, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Eligible Conditions
- Pancreatic Cancer
- Solid Tumors
- Non-Small Cell Lung Cancer
- Colon Cancer
- Thyroid Cancer
- Medullary Thyroid Cancer
- Breast Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
Loxo Oncology, Inc.Lead Sponsor
69 Previous Clinical Trials
10,302 Total Patients Enrolled
Eli Lilly and CompanyIndustry Sponsor
2,640 Previous Clinical Trials
3,221,644 Total Patients Enrolled
Contact Lilly at 1-800-LillyRx (1-800-545-5979)Study DirectorEli Lilly and Company
6 Previous Clinical Trials
95 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger